UT-MD Anderson Cancer Center: Nanotechnology Platform Enables Immune Conversion Of Cancer Cells, Sensitizing Them To Immunotherapy
November 11, 2022
November 11, 2022
HOUSTON, Texas, Nov. 11 (TNSjou) -- The University of Texas's MD Anderson Cancer Center issued the following news release:
* * *
Preclinical study uses nanoparticles to attach immune-activating molecule to tumors
* * *
A team of researchers at The University of Texas MD Anderson Cancer Center has developed a nanotechnology platform that can change the way the immune system sees solid tumor cells, making them more receptive to immunotherapy . . .
* * *
Preclinical study uses nanoparticles to attach immune-activating molecule to tumors
* * *
A team of researchers at The University of Texas MD Anderson Cancer Center has developed a nanotechnology platform that can change the way the immune system sees solid tumor cells, making them more receptive to immunotherapy . . .